Stock Scorer

BioXcel Therapeutics, Inc. (BTAI)

BioXcel Therapeutics, Inc. reported revenue of 182K USD for the quarter ending 30 June 2026, up 51.7% from 120K a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 182K +51.7%
Gross Profit Q2 '26 · ending 30 June 2026 160K +1130.8%
Operating Income Q2 '26 · ending 30 June 2026 -10.2M —
Net Income Q2 '26 · ending 30 June 2026 -14.7M —
Cost of Revenue Q2 '26 · ending 30 June 2026 22K -79.4%
Operating Cash Flow Q2 '26 · ending 30 June 2026 -6.1M —
Free Cash Flow Q2 '26 · ending 30 June 2026 -6.1M —
Shares Outstanding Q2 '26 · ending 30 June 2026 30.3M +526.8%
EPS Q2 '26 · ending 30 June 2026 -2.81 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 642K-50.5M-69.9M-57.6M
20242024-12-31 2.3M-67.2M-59.6M-72M
20232023-12-31 1.4M-171.8M-179.1M-155M
20222022-12-31 375K-159.6M-165.8M-135.5M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-30182K
Q1 '262026-03-31206K
Q4 '252025-12-31256K
Q3 '252025-09-3098K
Q2 '252025-06-30120K
Q1 '252025-03-31168K
Q4 '242024-12-31366K
Q3 '242024-09-30214K
Q2 '242024-06-301.1M
Q1 '242024-03-31582K
Q4 '232023-12-31376K
Q3 '232023-09-30341K
Q2 '232023-06-30457K
Q1 '232023-03-31206K
Q4 '222022-12-31238K
Q3 '222022-09-30137K
Q3 '182018-09-300
Q2 '182018-06-300
Q1 '182018-03-310
Q3 '172017-09-300

Gross Profit Quarterly

Revenue minus cost of sales. This filer tags no gross profit of its own..

PeriodEndingGross Profit
Q2 '262026-06-30160K
Q1 '262026-03-31-77K
Q4 '252025-12-31224K
Q3 '252025-09-3087K
Q2 '252025-06-3013K
Q1 '252025-03-31154K
Q4 '242024-12-31-466K
Q3 '242024-09-30-956K
Q2 '242024-06-301M
Q1 '242024-03-31502K
Q4 '232023-12-31-338K
Q3 '232023-09-30-171K
Q2 '232023-06-30431K
Q1 '232023-03-31197K
Q4 '222022-12-31229K
Q3 '222022-09-30126K

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-10.2M
Q1 '262026-03-31-10.2M
Q4 '252025-12-31-10.3M
Q3 '252025-09-30-14.2M
Q2 '252025-06-30-15.9M
Q1 '252025-03-31-10.1M
Q4 '242024-12-31-10.5M
Q3 '242024-09-30-15.3M
Q2 '242024-06-30-17.3M
Q1 '242024-03-31-24.2M
Q4 '232023-12-31-19.9M
Q3 '232023-09-30-48.3M
Q2 '232023-06-30-52.4M
Q1 '232023-03-31-51.2M
Q4 '222022-12-31-52.9M
Q3 '222022-09-30-39M
Q2 '222022-06-30-36.3M
Q1 '222022-03-31-31.5M
Q4 '212021-12-31-26.1M
Q3 '212021-09-30-26.8M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30-14.7M
Q1 '262026-03-31-12.7M
Q4 '252025-12-31-12.5M
Q3 '252025-09-30-30.9M
Q2 '252025-06-30-19.2M
Q1 '252025-03-31-7.3M
Q4 '242024-12-31-10.9M
Q3 '242024-09-30-13.7M
Q2 '242024-06-30-8.3M
Q1 '242024-03-31-26.8M
Q4 '232023-12-31-22.3M
Q3 '232023-09-30-50.5M
Q2 '232023-06-30-53.5M
Q1 '232023-03-31-52.8M
Q4 '222022-12-31-54.8M
Q3 '222022-09-30-41.8M
Q2 '222022-06-30-37.7M
Q1 '222022-03-31-31.5M
Q4 '212021-12-31-26.1M
Q3 '212021-09-30-26.8M

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q2 '262026-06-3022K
Q1 '262026-03-31283K
Q4 '252025-12-3132K
Q3 '252025-09-3011K
Q2 '252025-06-30107K
Q1 '252025-03-3114K
Q4 '242024-12-31832K
Q3 '242024-09-301.2M
Q2 '242024-06-3062K
Q1 '242024-03-3180K
Q4 '232023-12-31714K
Q3 '232023-09-30512K
Q2 '232023-06-3026K
Q1 '232023-03-319K
Q4 '222022-12-319K
Q3 '222022-09-3011K

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30-6.1M
Q1 '262026-03-31-11.8M
Q4 '252025-12-31-14.2M
Q3 '252025-09-30-18.8M
Q2 '252025-06-30-12.6M
Q1 '252025-03-31-12M
Q4 '242024-12-31-14.8M
Q3 '242024-09-30-16.3M
Q2 '242024-06-30-23.2M
Q1 '242024-03-31-17.7M
Q4 '232023-12-31-26.9M
Q3 '232023-09-30-37.6M
Q2 '232023-06-30-38.2M
Q1 '232023-03-31-52.4M
Q4 '222022-12-31-38.6M
Q3 '222022-09-30-31.2M
Q2 '222022-06-30-33.1M
Q1 '222022-03-31-32.4M
Q4 '212021-12-31-19.9M
Q3 '212021-09-30-20.2M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q2 '262026-06-30-6.1M
Q1 '262026-03-31-11.8M
Q4 '252025-12-31-14.2M
Q3 '252025-09-30-18.8M
Q2 '252025-06-30-12.6M
Q1 '252025-03-31-12M
Q4 '242024-12-31-14.8M
Q3 '242024-09-30-16.3M
Q4 '232023-12-31-26.9M
Q3 '232023-09-30-37.6M
Q4 '222022-12-31-38.6M
Q3 '222022-09-30-31.2M
Q2 '222022-06-30-33.1M
Q1 '222022-03-31-32.5M
Q4 '212021-12-31-19.9M
Q3 '212021-09-30-20.2M
Q2 '212021-06-30-22.5M
Q1 '212021-03-31-20M
Q4 '202020-12-31-20.5M
Q3 '202020-09-30-19.1M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-3030.3M
Q1 '262026-03-3123.6M
Q3 '252025-09-3014.2M
Q2 '252025-06-307.8M
Q1 '252025-03-314.8M
Q3 '242024-09-302.6M
Q2 '242024-06-302.5M
Q1 '242024-03-311.9M
Q3 '232023-09-3029.3M
Q2 '232023-06-3029.2M
Q1 '232023-03-3128.6M
Q3 '222022-09-3028M
Q2 '222022-06-3028M
Q1 '222022-03-3128K
Q3 '212021-09-3028M
Q2 '212021-06-3025M
Q1 '212021-03-3124.5M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q2 '262026-06-30-2.81
Q1 '262026-03-31-4.77
Q4 '252025-12-31-5.73
Q3 '252025-09-30-9.04
Q2 '252025-06-30-12.01
Q1 '252025-03-31-12.86
Q4 '242024-12-31-25.25
Q3 '242024-09-30-115.27
Q2 '242024-06-30-111.84
Q1 '242024-03-31-110.37
Q4 '232023-12-31-98.32
Q3 '232023-09-30-7.35
Q2 '232023-06-30-7.12
Q1 '232023-03-31-6.64
Q4 '212021-12-31-4.07
Q3 '212021-09-30-4.00
Q2 '212021-06-30-4.11
Q1 '212021-03-31-4.06
Q4 '202020-12-31-3.77
Q3 '202020-09-30-3.37